Phase 2 N=10 Assessment of Algorithm-Based Hydroxyurea Dosing on Fetal Hemoglobin Response, Acute Complications, and Organ Function in People With Sickle Cell Disease
Sickle Cell Disease
Primary: Fetal Hemoglobin Level — 8.3 Percentage
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=144 Omega-3 for Depression and Other Cardiac Risk Factors - 2
Depression
Primary: Beck Depression Inventory-II (BDI-II) — 29.9; 29.1; 11.0; 9.1 score on a scale
Phase 2 N=217 Dose Range Finding Study of Bimagrumab in Sarcopenia
Sarcopenia
Primary: Change From Baseline in Total Short Physical Performance Battery (SPPB) Score to Week 25 — 7.1; 7.3; 7.2; 7.3 Score on a scale — p=0.274
Phase 2 N=156 A Phase II Trial of Varenicline for the Treatment of Cocaine Dependence
Cocaine Dependence
Primary: Number of Participants Who Report no Cocaine Use and Have no Cocaine Positive Urine Drug Screens in the Chantix Group Versus the Placebo Group Comparator During the Last…
Phase 2 N=12 Ponatinib Hydrochloride in Treating Patients With Advanced Biliary Cancer With FGFR2 Fusions
Malignant Hepatobiliary Neoplasm
Primary: Clinical Benefit Rate (Percentage), Which Includes Confirmed Tumor Response (Complete Response [CR] or Partial Response [PR]) or Stable Disease (SD) — 45.5 percentage of…
Phase 2 N=158 A Study of Ramucirumab or Icrucumab in Colorectal Cancer
Colon Cancer · Rectal Cancer
Primary: Progression-Free Survival (PFS) — 18.4; 21.4; 15.9 Weeks
Phase 2 N=44 Superior Hypogastric Nerve Block for Pain Control Post-uterine Fibroid Embolization
Leiomyoma
Primary: mg Equivalent Morphine Used Until Discharge From Recovery Room to Control Pain Level Below 4/10 (VAS) — 11; 5.1 mg
Phase 2 N=61 A Clinical Trial to Assess the Safety of 0.005 % Estriol Vaginal Gel in Hormone Receptor-Positive Postmenopausal Women With Early Stage Breast Cancer in Treatment With Aromatase Inhibitor in the Adjuvant Setting
Vaginal Atrophy
Primary: Variation in Serum Levels of Follicle Stimulating Hormone (FSH) — -2.8; 1.4 mIU/ml — p=0.10
Phase 2 N=196 Improving Retreatment Success (IMPRESS)
Recurrent Tuberculosis
Primary: Sputum Culture Conversion Rates at Week 8 and Month 6 Post Tuberculosis Treatment Initiation — 78; 73; 84; 92 Participants — p=0.46
Phase 2 N=32 Immune-Modulated Study of Selected Small Molecules (Gefitinib, AZD9291, or Selumetinib + Docetaxel) or a 1st Immune-Mediated Therapy (IMT; Tremelimumab) With a Sequential Switch to a 2nd IMT (MEDI4736) in Patients With Locally Advanced or Metastatic Non-Small-Cell Lung Cancer
Locally Advanced or Metastatic Non-Small-Cell Lung Cancer (Stage IIIB-IV)
Primary: Confirmed Complete Response (CR) Rate — 0; 0 patients (%)
Phase 2 N=13 Guanfacine for the Treatment of Spatial Neglect and Impaired Vigilance
Stroke · Hemispatial Neglect
Primary: Performance on Tests of Hemispatial Neglect and Sustained Attention — 31.15; 26.15 Number of targets found — p=0.013
Phase 2 N=46 A 12-week Dose-Ranging Trial in Patients With Moderate to Severe Plaque Psoriasis
Plaque Psoriasis
Primary: Safety and Tolerability of IMO-8400 Compared With Placebo — 6; 6; 6; 5 adverse events — p=0.06
Phase 2 N=346 Safety and Immunogenicity of a 10 Valent Pneumococcal Conjugate Vaccine (SIILPCV10) in Healthy Adults, Toddlers, Infants
Pneumococcal Disease
Primary: Adult and Toddler Subjects Experiencing Local and Systemic Reactogenicity, by Severity — 0; 0; 5; 6 Participants
Phase 2 N=30 Effect of Chlorogenic Acid on Patients With Impaired Glucose Tolerance
Impaired Glucose Tolerance
Primary: Fasting Plasma Glucose (FPG) — 5.8; 5.5 mmol/L — p=0.004
Phase 2 N=47 Alemtuzumab to Treat Severe Aplastic Anemia
Severe Aplastic Anemia, Refractory · Severe Aplastic Anemia, Relapse
Primary: Number of Participants With Hematological Response at 6 Months — 0; 18 Participants